India’s Cut-Price Generics Program Rebounds But Real Impact Still Limited
India's cut-price generic drugs scheme appears to have gathered some pace, covering over 700 medicines, offering sharp price differentials over brand name therapies and also garnering some private sector interest. But its on-ground impact in improving affordable access to medicines is still limited, some experts claim.
You may also be interested in...
Increasing local content requirements have been stipulated in the public purchase preference norms for medicines in India. Backward-integrated Indian firms stand to gain but progressive localization requirements for drugs not made in India appear to be a tough ask.
India has outlined a set of initiatives to revive its thus far "unsatisfactory" "Jan Aushadhi" cut-price generic medicines scheme, including a distribution effort beyond the exclusive stores for these products and potentially even offering online purchases and home delivery.
An Indian government tender for more than 280 drugs under its ambitious "Jan Aushadhi" cut-price medicines program is expected to generate limited interest from leading private players, if the early responses of a number of experts is anything to go by.